PharmaSeek Implements Allegro CTMS for Clinical Research Site Management
MADISON, Wis., April 4, 2013 /PRNewswire/ -- Forte Research Systems, Inc., developer of specialized clinical research management software, announced that PharmaSeek, an Investigative Site Network, has implemented its Allegro Clinical Trial Management System (CTMS) to support their rapidly growing operations and help manage multiple trials running simultaneously. The investigative site network switched to the CTMS when they outgrew their existing system.
(Logo: http://photos.prnewswire.com/prnh/20101118/CG04162)
"We evaluated several CTMS systems and Forte allowed for an easy-to-use and highly-customizable platform. Forte's willingness to rely on feedback to continually make system updates and enhancements was critical in our decision making process," said Lindsay McCarthy, Director of Operations at PharmaSeek.
When beginning development of the multi-site edition of the Allegro CTMS system in 2011, Forte established collaboration with PharmaSeek so the network could provide insight and guidance with regard to the unique needs of networks.
The multi-site edition of Allegro CTMS was released in January 2012 with features such as a site database, project management tools, subject visit scheduling, and financial management functionality. After migrating all their data into the Allegro CTMS system, PharmaSeek has found the site selection and project management tools particularly useful.
"In Allegro CTMS, site selection is more streamlined than ever, allowing our team to quickly identify potential sites for new study opportunities," says McCarthy. "We are now able to quickly and easily retrieve qualified sites based on site-specific search criteria, such as therapeutic areas, phases a site can participate in, and equipment available at each site."
Additionally, contact information and documents such as investigator credentials are easily accessible, eliminating the need for repeated collection for each study protocol. The system also tracks expiration dates of these documents, so PharmaSeek can contact the site, if needed, to ensure they have the most current documents on file.
With the many activities and communications required during the study start-up process, PharmaSeek needed a way to manage all activities at each site. With Allegro CTMS, the PharmaSeek project managers are able to log in and view a dashboard for all the sites and protocols that they manage. They are also able to track metrics to gain insight into site performance across all these tasks.
McCarthy says, "Moving forward, we plan to dive deeper into Allegro CTMS, expanding the system to other areas of our organization and enabling us to manage everything from subject enrollments to budgets and payments."
About PharmaSeek
Based in Madison, WI, PharmaSeek is an Investigative Site Network that specializes in expediting clinical trials to a successful completion by securing investigative sites for Phase I through Phase IV clinical trials. With a network of 250 sites located throughout North America, PharmaSeek utilizes a CTMS to streamline processes and provide visibility into sites and study protocols.
About Forte Research Systems
Founded in 2000 and headquartered in Madison, Wisconsin, Forte Research Systems, Inc. develops and markets clinical and translational research management software for better compliance, safety, and financial viability. The company's flagship product, the OnCore® eClinical solution, has been meeting the needs of academic medical centers, CTSAs, research hospitals, and cancer centers for over a decade. For research sites, site networks, and SMOs, Forte offers Allegro® CTMS. Allegro systems are purpose-built, easy-to-use, and intuitively designed to support clinical research operations excellence. Forte is also host to the Clinical Research Blog and other resources for individuals interested in excellence in clinical research operations.
SOURCE Forte Research Systems, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article